CONGESTIVE HEART FAILURE
|
|
- Sylvia Bruce
- 6 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Plasma Homocysteine and Risk for Congestive Heart Failure in Adults Without Prior Myocardial Infarction Ramachandran S. Vasan, MD Alexa Beiser, PhD Ralph B. D Agostino, PhD Daniel Levy, MD Jacob Selhub, PhD Paul F. Jacques, ScD Irwin H. Rosenberg, MD Peter W. F. Wilson, MD CONGESTIVE HEART FAILURE (CHF) is a public health problem with considerable morbidity, mortality, and economic burden. 1,2 Thus, identification of risk factors for CHF is a public health priority. Several epidemiological investigations have identified advancing age, myocardial infarction (MI), hypertension, valve disease, diabetes mellitus, and obesity as key risk factors for CHF. 3-6 In the last decade, plasma total homocysteine has emerged as a major vascular disease risk factor. Elevated total homocysteine levels have been related to greater risk of atherosclerotic sequelae, including cardiovascular mortality, coronary heart disease, and stroke. 7-9 Prior investigations have not examined the relation of homocysteine to risk of CHF. In small clinical series, patients with CHF have been reported to have elevated plasma homocysteine levels. 10,11 Based on experimental evidence that the myocardium may be uniquely susceptible to homocysteine-induced injury 12 and observations relating homocysteine to Context Elevated plasma homocysteine levels are associated with increased risk of vascular disease. It is unclear whether elevated homocysteine levels are a risk factor for congestive heart failure (CHF). Objective To study prospectively the association between nonfasting plasma homocysteine and incidence of CHF. Design, Setting, and Participants Community-based prospective cohort study of 2491 adults (mean age 72 years, 1547 women) who participated in the Framingham Heart Study during the and examinations and were free of CHF or prior myocardial infarction (recognized or unrecognized) at baseline. Main Outcome Measure Incidence of a first episode of CHF during an 8-year follow-up period. Results During follow-up, 156 subjects (88 women) developed CHF. In multivariable analyses controlling for established risk factors for CHF including the occurrence of myocardial infarction (recognized or unrecognized) during follow-up, plasma homocysteine levels higher than the sex-specific median value were associated with an adjusted hazards ratio for heart failure of 1.93 in women (95% confidence interval, ) and 1.84 in men (95% confidence interval, ). The relation of plasma homocysteine levels to CHF risk was more continuous in women than in men. In analyses restricted to participants without any manifestation of coronary heart disease at baseline, the association of plasma homocysteine levels with risk of CHF was maintained in men and women. Conclusions An increased plasma homocysteine level independently predicts risk of the development of CHF in adults without prior myocardial infarction. Additional investigations are warranted to confirm these findings. JAMA. 2003;289: Author Affiliations: National Heart, Lung, and Blood Institute s Framingham Heart Study (Drs Vasan, Beiser, D Agostino, Levy, and Wilson), Framingham, Mass; Cardiology Section (Dr Vasan), Endocrinology Section (Dr Wilson), Preventive Medicine and Epidemiology (Drs Vasan, Levy, and Wilson), Department of Medicine, Boston University School of Medicine, and Department of Biostatistics, Boston University School of Public Health (Dr Beiser); and Department of Mathematics (Dr D Agostino), Boston University, Boston, Mass; the Divisions of Cardiology and Clinical Epidemiology, Beth Israel Deaconess Medical oxidative stress 13 and to left ventricular remodeling, 14,15 we hypothesized that elevated plasma homocysteine levels would increase the risk of CHF. Accordingly, we investigated the relations of plasma homocysteine concentration to the risk of CHF in a community-based sample of adults free of prior MI. Center (Dr Levy), Boston, Mass; and the National Heart, Lung, and Blood Institute, Bethesda, Md (Dr Levy); the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging (Drs Selhub, Jacques, and Rosenberg) at Tufts University, Boston, Mass. Financial Disclosure: Dr Wilson has served as a speaker for Abbott Laboratories. Corresponding Author and Reprints: Ramachandran S. Vasan, MD, Framingham Heart Study, 73 Mt Wayte Ave, Site 2, Framingham, MA ( vasan@fram.nhlbi.nih.gov) American Medical Association. All rights reserved. (Reprinted) JAMA, March 12, 2003 Vol 289, No
2 METHODS Participants The Framingham Heart Study began in 1948 as a prospective epidemiological investigation of 5209 women and men. 16 Participants in the original cohort are examined every 2 years. Attendees of the 16th biennial examination (1979 through 1982, 2351 subjects) and the 20th examination (1986 through 1990, 1401 subjects) were available for the present investigation because plasma homocysteine measurements were routinely obtained at these examinations. We excluded 1261 participants (33.9%) for the following reasons: missing information on covariates (n=730), lack of plasma homocysteine measurements (n=235), prevalent CHF (n=76), lack of follow-up (n=11), and prior recognized or unrecognized MI (n=209). Those with missing covariates were older and had slightly higher plasma homocysteine levels than those included in the sample. We chose to exclude individuals with a prior myocardial infarction because the demonstration of an association of homocysteine with CHF in such a sample would support the hypothesis that homocysteine promotes CHF risk even in the absence of clinically apparent preexisting myocardial injury. After the above exclusions, 2491 subjects (mean [SD] age was 72 [7] years [range, 60-95], 1547 women) remained eligible. Informed consent was obtained from study participants and the research protocol was reviewed and approved by the institutional review board of Boston University School of Medicine. Original cohort subjects who were eligible at the 16th examination cycle remained eligible for inclusion at the 20th biennial examination if they reached that examination free of CHF. The pooled sampling design enabled us to use plasma homocysteine measurements at 2 different examinations, each with 8 years of follow-up. At each examination, participants underwent a medical history, a physical examination (including blood pressure measurement), a 12-lead electrocardiogram, and systematic assessment of cardiovascular disease risk factors. Hypertension was defined as a systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of 90 mm Hg or higher, or pharmacological treatment of a previously elevated blood pressure. 17 Diabetes was determined by plasma glucose levels at the baseline examinations: fasting, 7.0 mmol/l (126 mg/dl), random nonfasting level of at least mmol/l (200 mg/dl), or the use of insulin or oral hypoglycemic agents. 18 Criteria for all other covariates have been described previously. 19 Plasma Homocysteine At the baseline examinations, plasma specimens were refrigerated immediately after phlebotomy and stored at or below 20 C. Plasma total homocysteine levels were measured subsequently in and in mid-1997 using high-performance liquid chromatography with fluorometric detection. 20 The coefficient of variation for this assay was 9%. 21 The stability of plasma homocysteine in samples stored at temperatures below 20 C has been documented. 22 Outcome All subjects were under continuous surveillance for the development of cardiovascular disease events including CHF and MI. A panel of 3 experienced investigators reviewed all suspected cardiovascular disease events by examining hospital records, information from physicians, and pathology reports using previously described methods. The primary outcome for our investigation, was the occurrence of a first episode of CHF as defined by the Framingham Heart Study criteria. 23 These validated criteria require the simultaneous presence of at least 2 major criteria, or 1 major criterion in conjunction with 2 minor criteria to establish a diagnosis. 24 Major criteria included paroxysmal nocturnal dyspnea or orthopnea, jugular venous distension, pulmonary rales, radiographic cardiomegaly, acute pulmonary edema, third heart sound, estimated central venous pressure of more than 16 cm of H 2 O, hepatojugular reflux; and weight loss of 4.5 kg in 5 days in response to receiving treatment for CHF. Minor criteria included bilateral ankle edema, nocturnal cough, dyspnea on ordinary exertion, hepatomegaly, pleural effusion, and heart rate of at least 120/min. Minor criteria were acceptable only if they could not be attributed to another medical condition (such as chronic lung disease, extreme obesity, cirrhosis, ascites, or nephrotic syndrome). Criteria for recognized and unrecognized MI have been detailed. 19 Statistical Analysis Follow-up was for 8 years. Sex-specific Cox proportional-hazards regression models 25 were used to examine the association of plasma homocysteine (quartiles) with the incidence of CHF. Homocysteine levels increased markedly with age 21 and differed slightly between the 2 sexes. Accordingly, plasma homocysteine quartiles were defined in 2 ways: (1) crude sex-specific quartiles, not adjusted for age and (2) age- and sexspecific quartiles, defined for each of several 5-year age categories. The assuption of proportionality of hazards was met. Cox models adjusted for the following covariates (all defined at the baseline examinations with the exception of subsequent MI) that influence CHF risk 4,6 and/or plasma homocysteine levels 26,27 : age, body mass index (as an indicator of obesity), ratio of total cholesterol to high-density lipoprotein cholesterol levels, valve disease, current cigarette smoking status, alcohol consumption, systolic blood pressure, antihypertensive medication use, diabetes mellitus, serum creatinine, occurrence of an MI (recognized or unrecognized) on follow-up (as a timedependent covariate), and examination cycle. Adjustment for MI on follow-up is important because elevated plasma homocysteine levels might predispose a person to the development of CHF by increasing risk of MI. 28 Because serum creatinine values were not obtained at examination 16, values obtained at the previous examination were used. Models using homocysteine quartiles compared risk of CHF in each of the 3 top quartiles with the first quar JAMA, March 12, 2003 Vol 289, No. 10 (Reprinted) 2003 American Medical Association. All rights reserved.
3 tile serving as a referent (multicategory models), and examined the trend across the quartiles (trend models). We also evaluated threshold models that compared the risk of CHF at select quartilebased cut points for plasma homocysteine levels, eg, values above vs those at or below the median, fourth quartile of plasma homocysteine vs the first 3 quartiles. Separate models were examined for crude sex-specific quartiles (model 1), and for age- and sex-specific quartiles (model 2) of plasma homocysteine concentration. We performed supplementary analyses treating homocysteine as a continuous variable (with natural logarithmic transformation); subjects with homocysteine values higher than 30 µmol/l were excluded for these analyses to avoid excessive influence of results by extreme values. Ancillary Analyses We tested for the presence of effect modification by age, systolic blood pressure, diuretic or cholesterol-lowering drug use, and the baseline examination by incorporating several interaction terms individually in multivariable models 1 (above median plasma homocysteine covariate; plasma homocysteine covariate). Because blood pressure is a key risk factor for CHF, we examined additional models that incorporated the average of several readings of systolic blood pressures obtained at Framingham study examinations in the decade preceding the baseline examination. Although we excluded all subjects with a recognized or unrecognized prior MI, we did not exclude subjects with a history of angina or coronary insufficiency (n=249, 151 women). We performed secondary analyses excluding those with prevalent coronary heart disease at baseline. Echocardiographic Insights To obtain insights into the type of CHF (systolic vs diastolic) associated with increasing plasma homocysteine concentration, we reviewed echocardiographic reports in a subgroup of participants who had evaluation of left ventricular systolic function within 30 days of their first hospitalization for CHF in a contemporary period (1989 to 1998). Heart failure was presumed to be due to systolic dysfunction (systolic CHF) if the estimated left ventricular ejection fraction was less than 50%, whereas a left ventricular ejection fraction of 50% or higher was considered consistent with diastolic CHF. 29 A 2-sided P value of.05 was considered significant. All analyses were performed using version 8 of the SAS statistical package. 30 RESULTS Clinical Characteristics About a quarter of our participants were hyperhomocysteinemic ( 14 µmol/l) at Table 1. Study Sample Characteristics baseline (TABLE 1). The sex-specific quartiles of plasma homocysteine overall and for 5-year age groups are in TABLE 2 (for pooled examinations). Homocysteine and CHF Risk During a follow-up period of 8 years, 156 subjects (88 women) developed CHF. The FIGURE indicates that the crude cumulative incidence of CHF in women and men in the top 2 homocysteine quartiles (values higher than the sex-specific median) was considerably higher than those in the lower 2 quartiles. During follow up, 6% of women and 12% of men in the sample experienced an MI (recognized or unrecognized). Of the incident CHF cases, 28 of the 88 women and 22 of the 68 Characteristics Women (n = 1547) Men (n = 944) Age, mean (SD), y 72.4 (7.0) 71.4 (6.9) Follow-up, y 7.3 ( ) 7.0 ( ) Body mass index, mean (SD) 26.5 (4.7) 26.9 (3.9) Current cigarette smoking, No. (%) 282 (18) 164 (17) Alcohol consumption, No. (%)* None 726 (47) 267 (28) Mild to moderate 521 (34) 405 (43) Heavy 300 (19) 272 (29) Blood pressure, mean (SD), mm Hg Systolic 142 (21) 142 (20) Diastolic 76 (10) 79 (10) Hypertension, No. (%) 1050 (68) 579 (61) Diabetes mellitus, No. (%) 114 (7) 107 (11) Cholesterol, mean (SD), mg/dl Total 235 (41) 214 (37) High-density lipoprotein 54 (16) 44 (13) Total/high-density lipoprotein ratio 4.7 (1.6) 5.3 (1.7) Serum creatinine, mean (SD), mg/dl 1.0 (0.3) 1.1 (0.3) Plasma homocysteine, mean (SD), µmol/l 12.0 (5.4) 13.0 (8.8) Plasma homocysteine 14 µmol/l, No. (%) 358 (23) 264 (28) ECG-LVH, No. (%) 34 (2) 19 (2) Valve disease, No. (%) 79 (5) 53 (6) Medication use, No. (%) Angiotensin-converting enzyme inhibitors 40 (3) 25 (3) Cholesterol-lowering agents 47 (3) 15 (2) Diuretics 540 (35) 213 (23) Hypertension treatment 696 (45) 331 (35) Non-MI coronary disease, No. (%) 151 (10) 98 (10) Abbreviations: ECG-LVH indicates electrocardiographic left ventricular hypertrophy; MI, myocardial infarction. SI conversion factors: To convert cholesterol from mg/dl to mmol/l, multiply by ; creatinine from mg/dl to µmol/l, multiply by *Alcohol consumption (none; mild to moderate, 1 drink/d in women and 2 drinks/d in men; heavy, 1 drink/d in women and 2 drinks/d in men). Values obtained at examination cycle 15 were used for subjects included at examination cycle 16. Subjects with MI were excluded; data refer to angina and coronary insufficiency American Medical Association. All rights reserved. (Reprinted) JAMA, March 12, 2003 Vol 289, No
4 men experienced an MI prior to the development of CHF. TABLE 3 shows the results of multivariable analyses examining the relations of plasma homocysteine levels to risk of CHF after adjusting for covariates at baseline and additionally for the occurrence of MI on follow-up. Use of age-adjusted quartiles of homocysteine yielded similar results to the use of crude quartiles. Risk of CHF increased about 25% (men) to 49% (women) per quartile increment in plasma homocysteine level (Table 3, models 1 and 2, trend across quartiles). Thresholds at which CHF risk increased in multicategory models (comparing each plasma homocysteine quartile with the first) were different for women and men (Table 3). In women, risk of CHF rose at the second plasma homocysteine quartile; the point estimates of the hazards ratios exceeded 2 for the second and the third quartiles relative to the lowest quartile. An additional increase in risk of CHF was observed at the top quartile of plasma homocysteine. Because of the increasing gradient of risk across plasma homocysteine quartiles, cut points at the median and the 75th percentile plasma homocysteine values were each associated with an about 2-fold risk of CHF relative to levels below these thresholds (P.01 for both). In men, risk of CHF increased only beyond the second quartile of plasma homocysteine; the point estimates of the hazards ratio for the third and fourth quartiles each exceeded 1 but were not statistically significant (in multicategory models). Values above the median were associated with an 84% to 92% increased risk of CHF (models 1 and 2, P.03 for both). The top quartile was associated with a 60% increased risk relative to the lower 3 quartiles. When considered as a continuous variable, increased plasma homocysteine levels were predictive of CHF in men (adjusted hazard ratio per 1 SD [0.4] increment in log homocysteine, 1.66; 95% confidence interval, ) and in women (adjusted hazards ratio per 1 SD [0.4] increment in log homocysteine, 1.34; 95% confidence interval, ). Table 2. Distribution of Baseline Plasma Homocysteine Levels Within 5-Year Age Groups and Overall* Women Men Homocysteine Quartile, µmol/l Homocysteine Quartile, µmol/l No. of Mean No. of Mean Age, y Women (SD) Men (SD) (5.0) (6.9) (4.2) (4.2) (5.6) (13.8) (4.5) (5.4) (6.6) (7.3) (7.2) (6.2) All ages (5.4) (8.8) Figure. Plasma Homocysteine and Congestive Heart Failure Risk A Women B Men 12 Quartiles 3-4 Cumulative Incidence of CHF, % Quartiles 3-4 Quartiles 1-2 Quartiles 1-2 No. at Risk Quartiles 1-2 Quartiles Time, y Time, y Kaplan-Meier plots showing the cumulative incidence of heart failure in subjects with baseline plasma homocysteine levels above the median (quartiles 3-4) compared with plasma homocysteine levels at or below the median (quartiles 1-2) JAMA, March 12, 2003 Vol 289, No. 10 (Reprinted) 2003 American Medical Association. All rights reserved.
5 Effect Modification Associations of homocysteine levels with CHF risk did not vary with age, systolic blood pressure, diuretic or cholesterol-lowering drug use, or baseline examination (P values for all interactions exceeded.10). Additionally, the relations of elevated homocysteine levels and CHF risk were maintained in analyses adjusting for the average of multiple systolic blood pressure readings obtained at examinations in the decade preceding the baseline examination. In secondary analyses excluding all individuals with any prevalent coronary heart disease at baseline, the relations of elevated homocysteine and CHF risk remained robust in women (TABLE 4). In men, the associations of the median-based threshold of plasma homocysteine with increased risk of CHF observed in primary analyses were maintained (Table 4). Echocardiographic Evaluation Of the 32 participants (20% of CHF cases) who underwent echocardiographic evaluation within 30 days of their first hospitalization for CHF, 13 (62%) of 21 of individuals with plasma homocysteine higher than the median, and 7 (64%) of 11 of those with plasma homocysteine levels below the median had a left ventricular ejection fraction of less than 50% (indicative of systolic CHF). COMMENT Principal Findings To our knowledge, this is the first report in the general population examining prospectively the relations of plasma homocysteine levels and risk of subsequent CHF in individuals without a prior MI. In our sample, elevated plasma homocysteine concentration was related positively and strongly to CHF risk in continuous fashion in women; risk of CHF doubled at the second quartile and a 4-fold risk was observed for those with values in the top quartile vs those whose values were in the lowest quartile. In men, the association of plasma homocysteine with risk of CHF became evident only at values exceeding the median. In both men and women, the increased risk of CHF associated with plasma homocysteine was consistent regardless of the method of defining quartiles (age-adjusted vs age-pooled). In analyses restricted to a subset of individuals without any clinical coronary disease at baseline, the association of plasma homocysteine with CHF risk was maintained in both men and women. In a small subgroup of individuals who underwent echocardiographic evaluation within 30 days of their first CHF hospitalization, elevated homocysteine levels (values median) were associated with both systolic and diastolic CHF. The sex-related differences in the thresholds of plasma homocysteine at which risk increases merits comment. It is well known that ischemic heart disease is a more important contributor to CHF risk in men, whereas hypertension accounts for a greater proportion of CHF risk in women. 4 This study design specifically examined the possibility that homocysteine may promote CHF through nonischemic mechanisms by excluding individuals with prior MI and by adjusting for interim development of MI. It is important to note that although the relative risk for CHF associated with the top quartile of plasma homocysteine vs the lowest quartile is higher in women than in men, the absolute risk of CHF is lower in women (Figure). 31 Table 3. Multivariable Cox Proportional Hazard Models for Risk of Congestive Heart Failure According to Plasma Homocysteine Levels* Quartile Trend Across Quartiles Models With Crude Sex-Specific Quartiles of Homocysteine Above Median vs Below Median Quartile 4 vs Quartiles 1-3 No. of women with CHF/ 10/386 (2.6) 16/389 (4.1) 20/385 (5.2) 42/387 (10.9) HR (95% CI) Referent 2.18 ( ) 2.21 ( ) 3.74 ( ) 1.47 ( ) 1.93 ( ) 2.11 ( ) P value No. of men with CHF/ 13/236 (5.5) 9/235 (3.8) 19/237 (8.0) 27/236 (11.4) HR (95% CI) Referent 0.61 ( ) 1.34 ( ) 1.57 ( ) 1.25 ( ) 1.84 ( ) 1.58 ( ) P value Models With Age- and Sex-Specific Quartiles of Plasma Homocysteine No. of women with CHF/ 10/384 (2.6) 19/386 (4.9) 25/392 (6.4) 34/385 (8.8) HR (95% CI) Referent 2.38 ( ) 3.04 ( ) 4.03 ( ) 1.49 ( ) 2.09 ( ) 1.88 ( ) P value No. of men with CHF/ 13/233 (5.6) 10/238 (4.2) 20/237 (8.4) 25/236 (10.6) HR (95% CI) Referent 0.56 ( ) 1.34 ( ) 1.50 ( ) 1.26 ( ) 1.92 ( ) 1.60 ( ) P value Abbreviations: CI, confidence interval; HR, hazards ratio. *All models are adjusted for age, smoking, valve disease, systolic blood pressure, antihypertensive medication use, echocardiographic left ventricular hypertrophy, diabetes, ratio of total cholesterol to high-density lipoprotein, alcohol intake, body mass index, serum creatinine, interim recognized or unrecognized myocardial infarction, and baseline examination American Medical Association. All rights reserved. (Reprinted) JAMA, March 12, 2003 Vol 289, No
6 Mechanisms The strength of the association (hazards ratio of about 2.0 for values median), the demonstration of a temporal sequence (increased homocysteine levels preceded the development of CHF), and the consistency of results in multiple analyses raise the possibility of a causal relation between increased plasma homocysteine levels and risk of CHF. An alternative interpretation is that individuals with subclinical left ventricular dysfunction have elevated plasma homocysteine levels, perhaps due to renal hypoperfusion, and these participants develop overt CHF on follow up (reverse causality). Recent experimental studies have underscored that the myocardium is uniquely susceptible to homocysteineinduced injury. 12 Neither cystathionine synthase (the key enzyme for the transsulfuration pathway of homocysteine metabolism) nor betaine-homocysteine methyltrasferase (major enzyme for the alternate remethylation pathway) are expressed in myocardial cells, rendering cardiac myocytes critically dependent on the methionine synthase remethylation pathway. 12 Elevated homocysteine levels may promote CHF through several mechanisms. First, elevated homocysteine concentration is a risk factor for coronary atherosclerosis 32,33 and MI, 28 the latter being a key antecedent of CHF. 4 Furthermore, homocysteine may cause myocardial ischemia in the absence of infarction by promoting endothelial dysfunction of coronary resistance vessels Second, elevated homocysteine levels in patients with acute coronary syndromes are associated with greater myocardial injury as evidenced by higher troponin levels. 37 As noted above, we accounted for these possibilities to some extent by excluding all individuals with an MI (recognized or unrecognized) at baseline, and by further adjusting for interim MI (either recognized or unrecognized) on follow-up. Third, investigators have emphasized the critical role of homocysteine as a source of increased oxidative stress, a factor known to promote myocardial dysfunction. 13 Fourth, hyperhomocysteinemic rats have increased cardiac fibrosis and increased activation of matrix metalloproteinases, which in turn promote left ventricular remodeling, a known precursor of CHF. 14 A similar adverse effect of homocysteine on left ventricular remodeling has been noted in the setting of renal failure in humans. 15 Although all these mechanisms may be operative, our study design would support the importance of nonischemic mechanisms in addition to the wellrecognized ischemic mechanisms. Additional experimental investigations are warranted to examine the relative contributions of ischemic and nonischemic to the increased risk of CHF associated with elevated plasma homocysteine levels. The strengths of our investigation include the large community-based sample, the standardized measurement of homocysteine, the use of consistent criteria for the diagnosis of CHF, and the use of measurements of plasma homocysteine concentrations at 2 different time points. Nonetheless, it is important to acknowledge several limitations. Plasma homocysteine levels were obtained on participants in a nonfasting state and, therefore, were likely to be slightly higher than if fasting specimens had been obtained. 38 Use of a single estimation of plasma homocysteine may underestimate Table 4. Multivariable Cox Proportional Hazard Models for Risk of Congestive Heart Failure According to Plasma Homocysteine Levels: Excluding All Prevalent Coronary Heart Disease at Baseline* Quartile Trend Across Quartiles Models With Crude Sex-Specific Quartiles of Homocysteine Above Median vs Below Median Quartile 4 vs Quartiles 1-3 No. of women with CHF/ 9/351 (2.6) 11/349 (3.2) 17/346 (4.9) 37/350 (10.6) HR (95% CI) Referent 1.50 ( ) 1.93 ( ) 3.07 ( ) 1.45 ( ) 2.04 ( ) 2.03 ( ) P value No. of men with CHF/ 10/205 (4.9) 9/217 (4.2) 16/214 (7.5) 23/210 (11.0) HR (95% CI) Referent 0.85 ( ) 1.64 ( ) 1.69 ( ) 1.25 ( ) 1.81 ( ) 1.45 ( ) P value Models With Age- and Sex-Specific Quartiles of Plasma Homocysteine No. of women with CHF/ 8/345 (2.3) 15/349 (4.3) 21/351 (6.0) 30/351 (8.6) HR (95% CI) Referent 1.91 ( ) 3.02 ( ) 3.54 ( ) 1.46 ( ) 2.20 ( ) 1.77 ( ) P value No. of men with CHF/ 10/203 (4.9) 10/218 (4.6) 17/215 (7.9) 21/210 (10.0%) HR (95% CI) Referent 0.75 ( ) 1.61 ( ) 1.63 ( ) 1.27 ( ) 1.90 ( ) 1.49 ( ) P value Abbreviations: CI, confidence interval; HR, hazards ratio. *All models are adjusted for age, smoking, valve disease, systolic blood pressure, antihypertensive medication use, echocardiographic left ventricular hypertrophy, diabetes, ratio of total cholesterol to high-density lipoprotein, alcohol intake, body mass index, serum creatinine, interim recognized or unrecognized myocardial infarction, and baseline examination JAMA, March 12, 2003 Vol 289, No. 10 (Reprinted) 2003 American Medical Association. All rights reserved.
7 associated disease risk on follow-up. 39 As these analyses reflect the experience of participants through 1997, the data may have limited relevance to the current era of folic acid fortification of cereal grain flour in the United States, which began voluntarily in March 1996, and by the US Food and Drug Administration mandate on January 1, Lastly, our study sample was almost exclusively white, which reduces the generalizability of our results to other ethnic groups. Our findings are consistent with the hypothesis that elevated plasma homocysteine levels are an important risk factor for CHF. The finding of a doubling of CHF risk in women with plasma homocysteine levels in the second quartile, at levels hitherto considered normal, is provocative. Given the novelty of our findings, we would like to underscore the need for additional studies to corroborate our results. Also, experimental investigations are required to clarify further the pathophysiological mechanisms underlying the observed association and the sex-related differences observed in our sample. If our observational findings are confirmed, additional studies (clinical trials) will be required to examine the possibility that lowering elevated homocysteine levels through vitamin therapy with folic acid, 41 alone or in combination with pyridoxine hydrochloride and cyanocobalamin may reduce the risk of CHF. Author Contributions: Study concept and design: Vasan, Beiser, Selhub, Wilson. Acquisition of data: D Agostino, Selhub. Analysis and interpretation of data: Vasan, Beiser, D Agostino, Levy, Jacques, Rosenberg, Wilson. Drafting of the manuscript: Vasan, Wilson. Critical revision of the manuscript for important intellectual content: Vasan, Beiser, D Agostino, Levy, Selhub, Jacques, Rosenberg, Wilson. Statistical expertise: Beiser, D Agostino, Jacques. Obtained funding: Vasan, D Agostino, Selhub. Administrative, technical, or material support: Levy, Selhub. Study supervision: Vasan, Rosenberg, Wilson. Funding/Support: This work was supported in part through National Institutes of Health/National Heart, Lung, and Blood Institute Contract N01-HC-25195, 1K24 HL04334/NHLBI (Dr Vasan), and R01 HL Dr Wilson was partly supported by a grant from Roche Laboratories. This project was also supported by the US Department of Agriculture under cooperative agreement No Disclaimer: Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the US Department of Agriculture. REFERENCES 1. American Heart Association Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000:19-20, McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure. Eur Heart J. 1998; 19(suppl P):P9-P Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J. 1997;18: Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275: Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men. JIntern Med. 2001;249: Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347: Bostom AG, Selhub J. Homocysteine and arteriosclerosis. Circulation. 1999;99: Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease. Ann Intern Med. 1999;131: Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49: Cooke GE, Eaton GM, Whitby G, et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J Am Coll Cardiol. 2000;36: Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism. 2001; 50: Chen P, Poddar R, Tipa EV, et al. Homocysteine metabolism in cardiovascular cells and tissues. Adv Enzyme Reg. 1999;39: Loscalzo J. The oxidant stress of hyperhomocyst (e)inemia. J Clin Invest. 1996;98: Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens. 2002;15: Blacher J, Demuth K, Guerin AP, et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol. 1999;12: Dawber TR, Meadors GF, Moore FE. Epidemiologic approaches to heart disease: the Framingham Study. Am J Public Health. 1951;41: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157: Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, I. Diabet Med. 1998;15: Kannel WB, Wolf PA, Garrison RJ, eds. Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death in Pooled Repeated Biennial Measurements: Framingham Heart Study, 30 Year Follow-up. Bethesda, Md: US Dept of Health and Human Services; Section Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high- performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422: Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270: Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum. Clin Chem. 1993;39: McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure. N Engl J Med. 1971;285: Mosterd A, Deckers JW, Hoes AW, et al. Classification of heart failure in population based research. Eur J Epidemiol. 1997;13: Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972;34(series B): Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr. 2001;73: Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. JAMA. 1995;274: Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart. 1999;82: Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101: The PHREG Procedure. Changes and enhancements, through release Cary, NC: SAS Institute, Inc; Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20: Chao CL, Tsai HH, Lee CM, et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 1999; 147: Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338: Lentz SR. Homocysteine and vascular dysfunction. Life Sci. 1997;61: Chilian WM. Coronary microcirculation in health and disease. Circulation. 1997;95: Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyperhomocysteinemia evoked by folate depletion. Arterioscler Thromb Vasc Biol. 2002;22: Al Obaidi MK, Stubbs PJ, Collinson P, Conroy R, Graham I, Noble MI. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol. 2000; 36: Nurk E, Tell GS, Nygard O, Refsum H, Ueland PM, Vollset SE. Plasma total homocysteine is influenced by prandial status in humans: the Hordaland Homocysteine Study. J Nutr. 2001;131: Clarke R, Lewington S, Donald A, et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk. 2001;8: Food standards: amendment of standards of identity for enriched grain products to require additional folic acid. Fed Register. 1996;61: Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340: American Medical Association. All rights reserved. (Reprinted) JAMA, March 12, 2003 Vol 289, No
The New England Journal of Medicine
The New England Journal of Medicine Copyright 2002 by the Massachusetts Medical Society VOLUME 347 A UGUST 1, 2002 NUMBER 5 OBESITY AND THE RISK OF HEART FAILURE SATISH KENCHAIAH, M.D., JANE C. EVANS,
More informationORIGINAL INVESTIGATION. Profile for Estimating Risk of Heart Failure
ORIGINAL INVESTIGATION Profile for Estimating Risk of Heart Failure William B. Kannel, MD, MPH; Ralph B. D Agostino, PhD; Halit Silbershatz, PhD; Albert J. Belanger, MS; Peter W. F. Wilson, MD; Daniel
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationThe Whitehall II study originally comprised 10,308 (3413 women) individuals who, at
Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 2001 by the Massachusetts Medical Society VOLUME 345 N OVEMBER 1, 2001 NUMBER 18 IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE
More informationTHE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease
THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationthe U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations
Cardioprotection: What is it? Who needs it? William B. Kannel, MD, MPH From the Department of Preventive Medicine and Epidemiology, Evans Department of Clinical Research, Boston University School of Medicine,
More informationTEN-YEAR ABSOLUTE RISK ESTImates
ORIGINAL CONTRIBUTION CLINICIAN S CORNER Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Scan for Author Video Interview John T. Wilkins, MD, MS Hongyan Ning, MD, MS Jarett Berry, MD,
More informationHomocysteine and heart failure: a review of investigations from the Framingham Heart Study
Article in press - uncorrected proof Clin Chem Lab Med 2005;43(10):987 992 2005 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2005.173 2005/229 Review Homocysteine and heart failure: a review
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationClinical Correlates and Prognostic Significance of Exercise-Induced Ventricular Premature Beats in the Community. The Framingham Heart Study
Clinical Correlates and Prognostic Significance of Exercise-Induced Ventricular Premature Beats in the Community The Framingham Heart Study Ali Morshedi-Meibodi, MD; Jane C. Evans, DSc; Daniel Levy, MD;
More informationFolate, vitamin B 6, and vitamin B 12 are cofactors in
Research Letters Dietary Folate and Vitamin B 6 and B 12 Intake in Relation to Mortality From Cardiovascular Diseases Japan Collaborative Cohort Study Renzhe Cui, MD; Hiroyasu Iso, MD; Chigusa Date, MD;
More informationInflammation, as Measured by the Erythrocyte Sedimentation Rate, Is an Independent Predictor for the Development of Heart Failure
Journal of the American College of Cardiology Vol. 45, No. 11, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.02.066
More informationHigh-Normal Blood Pressure Progression to Hypertension in the Framingham Heart Study
22 High- Blood Pressure Progression to Hypertension in the Framingham Heart Study Mark Leitschuh, L. Adrienne Cupples, William Kannel, David Gagnon, and Aram Chobanian This study sought to determine if
More informationREVIEW ARTICLE. Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease
Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease Causal or Casual? REVIEW ARTICLE William G. Christen, ScD; Umed A. Ajani, MBBS; Robert J. Glynn, ScD; Charles H. Hennekens, MD
More informationALLHAT. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationSupplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
More informationORIGINAL INVESTIGATION. Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study
ORIGINAL INVESTIGATION s and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study Vivian M. Abascal, MD; Martin G. Larson, ScD; Jane C. Evans, MPH; Ana T. Blohm, BA; Kim Poli,
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 2002 by the Massachusetts Medical Society VOLUME 347 O CTOBER 31, 2002 NUMBER 18 LONG-TERM TRENDS IN THE INCIDENCE OF AND SURVIVAL WITH HEART FAILURE DANIEL
More informationThe presence of cardiovascular disease risk factors, clinical
The Impact of JNC-VI Guidelines on Treatment Recommendations in the US Population Paul Muntner, Jiang He, Edward J. Roccella, Paul K. Whelton Abstract Using epidemiological and clinical trial evidence,
More informationTemporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality. The Framingham Heart Study
Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study Thomas J. Wang, MD; Martin G. Larson, ScD; Daniel Levy, MD; Ramachandran
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHypertension, Antihypertensive Treatment, and Sudden Coronary Death. The Framingham Study WILLIAM B. KANNEL, L. ADRIENNE CUPPLES, RALPH B.
Hypertension, Antihypertensive Treatment, and Sudden Coronary Death The Framingham Study WILLIAM B. KANNEL, L. ADRIENNE CUPPLES, RALPH B. AND JOSEPH STOKES IE D'AGOSTINO, SUMMARY During 30 years of follow-up,
More informationSurvival Associated with Two Sets of Diagnostic Criteria for Congestive Heart Failure
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 160, No. 7 Printed in U.S.A. DOI: 10.1093/aje/kwh268 Survival Associated
More informationLifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study
Diabetes Care Publish Ahead of Print, published online May 5, 2008 Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More informationPreventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex
Prevention and Rehabilitation Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Nathan D. Wong, PhD, a Gaurav Thakral, BS, a Stanley S. Franklin,
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationHeart Failure Dr ahmed almutairi Assistant professor internal medicin dept
Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept (MBBS)(SBMD) Introduction Epidemiology Pathophysiology diastolic/systolic Risk factors Signs and symptoms Classification of HF
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationStroke is the third leading cause of death in the
Probability of Stroke: A Risk Profile From the Framingham Study Philip A. Wolf, MD; Ralph B. D'Agostino, PhD; Albert J. Belanger, MA; and William B. Kannel, MD A health risk appraisal function has been
More informationThe New England Journal of Medicine LEFT VENTRICULAR DILATATION AND THE RISK OF CONGESTIVE HEART FAILURE IN PEOPLE WITHOUT MYOCARDIAL INFARCTION
LEFT VENTRICULAR DILATATION AND THE RISK OF CONGESTIVE HEART FAILURE IN PEOPLE WITHOUT MYOCARDIAL INFARCTION RAMACHANDRAN S. VASAN, M.D., MARTIN G. LARSON, SC.D., EMELIA J. BENJAMIN, M.D., SC.M., JANE
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationHigh Density Lipoprotein Cholesterol and Mortality
High Density Lipoprotein Cholesterol and Mortality The Framingham Heart Study Peter W.F. Wilson, Robert D. Abbott, and William P. Castelli In 12 years of follow-up for 2748 Framingham Heart Study participants
More informationHomocysteine as a Predictive Factor for Hip Fracture in Older Persons
The new england journal of medicine original article Homocysteine as a Predictive Factor for Hip Fracture in Older Persons Robert R. McLean, M.P.H., Paul F. Jacques, D.Sc., Jacob Selhub, Ph.D., Katherine
More informationATRIAL FIBRILLATION (AF) IS
ORIGINAL CONTRIBUTION Pulse Pressure and Risk of New-Onset Atrial Fibrillation Gary F. Mitchell, MD Ramachandran S. Vasan, MD Michelle J. Keyes, MA Helen Parise, ScD Thomas J. Wang, MD Martin G. Larson,
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationPage down (pdf converstion error)
1 of 6 2/10/2005 7:57 PM Weekly August6, 1999 / 48(30);649-656 2 of 6 2/10/2005 7:57 PM Achievements in Public Health, 1900-1999: Decline in Deaths from Heart Disease and Stroke -- United States, 1900-1999
More informationDUKECATHR Dataset Dictionary
DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35) Table of
More informationAsubstantial body of evidence from observational epidemiological
Effect of Dietary Patterns on Serum Homocysteine Results of a Randomized, Controlled Feeding Study Lawrence J. Appel, MD, MPH; Edgar R. Miller III, MD, PhD; Sun Ha Jee, PhD; Rachael Stolzenberg-Solomon,
More informationEarly-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study
Early-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study The Harvard community has made this article openly available. Please
More informationHomocysteine and ischaemic stroke in men: the Caerphilly study
J Epidemiol Community Health 2001;55:91 96 91 Homocysteine and ischaemic stroke in men: the Caerphilly study U B Fallon, P Elwood, Y Ben-Shlomo, J B Ubbink, R Greenwood, G Davey Smith Department of Social
More informationA study of Brain Natriuretic Peptide levels in acute cardiac failure
Original Research Article A study of Brain Natriuretic Peptide levels in acute cardiac failure Bhavik Prajapati 1*, Anirudh Kulkarni 2 1 Assistant Professor, Department of Medicine, SMS Multispecialty
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationHospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension
(2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with
More informationElevated serum homocysteine level has a positive correlation with serum cardiac troponin I in patients with acute myocardial infarction
Bangladesh Med Res Counc Bull 2012; 38: 9-13 Elevated serum homocysteine level has a positive correlation with serum cardiac troponin I in patients with acute myocardial infarction Abstract Alam N, Khan
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationORIGINAL INVESTIGATION. Risk Factors for Congestive Heart Failure in US Men and Women
ORIGINAL INVESTIGATION Risk Factors for Congestive Heart Failure in US Men and Women NHANES I Epidemiologic Follow-up Study Jiang He, MD, PhD; Lorraine G. Ogden, MS; Lydia A. Bazzano, PhD; Suma Vupputuri,
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationHEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM
REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,
More informationImpact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function. Sex-Related Differences in the Framingham Heart Study
Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function Sex-Related Differences in the Framingham Heart Study Martin K. Rutter, MB, ChB; Helen Parise, ScD; Emelia J. Benjamin,
More informationCoronary heart disease (CHD) is the leading cause of
Serum Albumin and Risk of Myocardial Infarction and All-Cause Mortality in the Framingham Offspring Study Luc Djoussé, MD, DSc; Kenneth J. Rothman, DrPH; L. Adrienne Cupples, PhD; Daniel Levy, MD; R. Curtis
More informationCharacteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study
ORIGINAL PAPER Characteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study Yi Zhang, MD, PhD; 1 Helene Lelong, MD; 2 Sandrine
More informationORIGINAL INVESTIGATION. Elevated Midlife Blood Pressure Increases Stroke Risk in Elderly Persons
Elevated Midlife Blood Increases Stroke Risk in Elderly Persons The Framingham Study ORIGINAL INVESTIGATION Sudha Seshadri, MD; Philip A. Wolf, MD; Alexa Beiser, PhD; Ramachandran S. Vasan, MD; Peter W.
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationStroke A Journal of Cerebral Circulation
Stroke A Journal of Cerebral Circulation JULY-AUGUST VOL. 7 1976 NO. 4 Components of Blood Pressure and Risk of Atherothrombotic Brain Infarction: The Framingham Study WILLIAM B. KANNEL, M.D., THOMAS R.
More informationAssociation of Parental Heart Failure with Risk of Heart Failure in Offspring
The new england journal of medicine original article Association of Parental Heart Failure with Risk of Heart Failure in Offspring Douglas S. Lee, M.D., Ph.D., Michael J. Pencina, Ph.D., Emelia J. Benjamin,
More informationANUMBER OF EPIDEMIOLOGIcal
ORIGINAL INVESTIGATION The Independent Effect of Type Diabetes Mellitus on Ischemic Heart Disease, Stroke, and Death A Population-Based Study of Men and Women With Years of Follow-up Thomas Almdal, DMSc;
More informationJournal of the American College of Cardiology Vol. 50, No. 11, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 11, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.05.035
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More informationEHMRG SCORE STUDY version 6.2; date: 11Jul11 PI: Dr. Douglas Lee. Study Background
EHMRG SCORE STUDY version 6.2; date: 11Jul11 PI: Dr. Douglas Lee Study Background Heart failure (HF) is a leading cause of morbidity and cardiovascular mortality. The burden of HF has increased over time
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationSaudi Journal of Medicine (SJM)
Saudi Journal of Medicine (SJM) Scholars Middle East Publishers Dubai, United Arab Emirates Website: http://scholarsmepub.com/ ISSN 2518-3389 (Print) ISSN 2518-3397 (Online) A Clinical Study of Chronic
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationVitamin D & Cardiovascular Disease
Vitamin D & Cardiovascular Disease Disclosures None Vitamin D Objectives: Discuss the basics of vitamin D metabolism Discuss the role of vitamin D deficiency in the development of coronary disease Review
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationKey words: Risk factor. Hyperhomocysteinemia. Ischemic heart disease. Smoking.
j c p s p September 2004 Volume 14 Number 09 September 2004 Home JCPSP Home Sep JCPSP Contents Email JCPSP HYPERHOMOCYSTEINEMIA AS A RISK FACTOR FOR ISCHEMIC HEART DISEASE Muhammad Aamir, Abdus Sattar,*
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationNormal systolic blood pressure and risk of heart failureinusmalephysicians
European Journal of Heart Failure (2009) 11, 1129 1134 doi:10.1093/eurjhf/hfp141 Normal systolic blood pressure and risk of heart failureinusmalephysicians Kathryn A. Britton 1,2 *, J. Michael Gaziano
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationBaldness and Coronary Heart Disease Rates in Men from the Framingham Study
A BRIEF ORIGINAL CONTRIBUTION Baldness and Coronary Heart Disease Rates in Men from the Framingham Study The authors assessed the relation between the extent and progression of baldness and coronary heart
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationComparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study
80 Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study Thomas Truelsen, MB; Ewa Lindenstrtfm, MD; Gudrun Boysen, DMSc Background and Purpose We wished to
More information